Granted Patent B2

US 8,188,224 · App. 11/918,297 · Granted May 29, 2012

Abstract

Claims (13)

1. An isolated truncated mammalian uricase comprising a mammalian uricase amino acid sequence truncated at the amino terminus or the carboxy terminus or both the amino and carboxy termini by 1-6 amino acids and further comprising an amino acid substitution with threonine at position 7 (D7T), an amino acid substitution with threonine at position 46 (S46T), an amino acid substitution with lysine at position 291 (R291K) and an amino acid substitution with serine at position 301 (T301S), said truncation and amino acid substitution being relative to a naturally occurring pig uricase having an amino acid sequence of SEQ ID NO: 11.

2. The uricase of claim 1 further comprising an amino terminal amino acid, wherein the amino terminal amino acid is alanine, glycine, proline, serine, or threonine.

3. The uricase of claim 2 wherein the amino terminal amino acid is threonine.

4. The uricase of claim 1 consisting of the amino acid sequence of SEQ ID NO. 8.

5. A polyethylene glycol-uricase conjugate comprising the uricase of claim 1 .

6. The conjugate of claim 5 , comprising 2 to 12 polyethylene glycol molecules on each uricase subunit.

7. The conjugate of claim 5 , wherein each polyethylene glycol molecule has a molecular weight between about 1 kD and 50 kD.

8. The conjugate of claim 7 , wherein each polyethylene glycol molecule has a molecular weight between about 5 kD and 20 kD.

9. A pharmaceutical composition comprising a conjugate of claim 5 .

10. A method of reducing uric acid levels in a biological fluid of a subject in need thereof, comprising administering the composition of claim 9 to the subject.

11. An isolated uricase comprising the amino acid sequence of SEQ ID NO. 14.

12. The isolated truncated mammalian uricase protein of claim 1 wherein the N-terminal amino acid is methionine.

13. The uricase of claim 12 comprising the amino acid sequence of SEQ ID NO. 7.

Assignments (15)